Mesirow Financial has expanded its investment banking coverage into the healthcare market through the addition of J. Andrew Cowherd and Paul Teitelbaum who join the firm in New York as new managing directors. Both bring to the firm experience in middle-market merger and acquisition advisory and financing in the healthcare sector.
“We are excited to expand our practice into the healthcare arena. The addition of Andy and Paul is a perfect complement to our existing platform, where we are consistently focused on achieving the strategic and financial goals of our clients across a variety of industries. Their middle-market advisory experience and in-depth knowledge of the healthcare sector will help us continue to elevate our clients’ experience by providing insightful advisory at the highest level of service,” said Jeffrey Golman, vice chairman and head of Mesirow Financial Investment Banking.
Mr. Cowherd joins Mesirow Financial with more than 35 years of investment banking and private equity experience, and with a healthcare specialization spanning over three decades. Prior to joining the firm, he served as a managing director at Peter J. Solomon Company with a focus on healthcare services and healthcare IT. He was previously a founding member and general partner of a private equity fund, Atlantic Medical Capital, and served as managing director at BT Securities and Salomon Brothers. Mr. Cowherd received his BA from Princeton and an MBA from Stanford.
Mr. Teitelbaum brings nearly 25 years of healthcare investment banking, company operating and consulting experience to Mesirow Financial. Prior to joining the firm, Mr. Teitelbaum served as managing director and head of healthcare investment banking at Landmark Ventures where he focused on medical device, healthcare IT and biopharmaceutical transactions. He also previously served as a senior healthcare investment banker at Burnham Securities and Nexus Health Capital, and as a senior associate at Robertson Stephens & Co. Prior to investment banking, he served in corporate development, sales and disease management roles at Wyeth-Lederle and Schering-Plough, and consulted for the FDA, EPA, DoD and Fortune 500 companies on toxicology and healthcare issues. Mr. Teitelbaum earned a BA from the University of Pennsylvania and an MBA from Wharton.
Mesirow Financial’s Investment Banking group focuses exclusively on middle-market transactions and serves established middle-market companies and large corporations, both public and private, in merger and acquisition advisory, capital markets advisory, restructuring and special situations, fairness and solvency opinion, board of directors advisory and special committee representation. Overall, Mesirow Financial is a diversified financial services firm with particular expertise in investment management, global markets, insurance services and consulting. Founded in 1937, Mesirow is an independent, employee-owned firm with more than 1,200 employees in offices across the US and in London, UK. The firm is headquartered in Chicago, IL (www.mesirowfinancial.com).
